Approved and authorised for issue by the Board of Directors on

Approved and authorised for issue by the board of

This preview shows page 30 - 33 out of 92 pages.

Approved and authorised for issue by the Board of Directors on October 28, 2019 and signed for and on behalf of the Board : Salman F Rahman Vice Chairman Dhaka October 28, 2019 Per our report of even date M.J. Abedin & Co. Chartered Accountants Nazmul Hassan Managing Director Mohammad Ali Nawaz Chief Financial Officer
Image of page 30
Amount in Taka Share Capital Share Premium Excess of Issue Price over Face Value of GDRs Capital Reserve on Merger Revaluation Surplus Unrealized Gain/ (Loss) Retained Earnings Total Balance as on July 01, 2018 4,055,564,450 5,269,474,690 1,689,636,958 294,950,950 1,159,277,845 4,356,762 14,631,128,276 27,104,389,931 Total Comprehensive Income for the year: Profit for the Year Other Comprehensive Income/(Loss) - - - - - - - - - - - (1,852,559) 3,023,500,974 - 3,023,500,974 (1,852,559) Transactions with the Shareholders: Cash Dividend - - - - - - (506,945,556) (506,945,556) Adjustment for the Depreciation on Revalued Assets - - - - (9,175,291) - 9,175,291 - Adjustment for Deferred Tax on Revalued Assets - - - - (18,249,550) - - (18,249,550) Balance as on June 30 ,2019 4,055,564,450 5,269,474,690 1,689,636,958 294,950,950 1,131,853,004 2,504,203 17,156,858,985 29,600,843,240 Net Asset Value (NAV) Per Share (Note-37) 72.99 For the Year ended June 30, 2018 Share Capital Share Premium Excess of Issue Price over Face Value of GDRs Capital Reserve on Merger Revaluation Surplus Unrealized Gain/ (Loss) Retained Earnings Total Balance as on July 01, 2017 4,055,564,450 5,269,474,690 1,689,636,958 294,950,950 1,190,203,818 3,875,065 12,568,719,969 25,072,425,900 Total Comprehensive Income for the year: Profit for the Year Other Comprehensive Income - - - - - - - - - - - 481,697 2,558,971,263 - 2,558,971,263 481,697 Transactions with the Shareholders: Cash Dividend - - - - - - (506,945,556) (506,945,556) Adjustment for the Depreciation on Revalued Assets - - - - (10,382,600) - 10,382,600 - Adjustment for Deferred Tax on Revalued Assets - - - - (20,543,373) - - (20,543,373) Balance as on June 30, 2018 4,055,564,450 5,269,474,690 1,689,636,958 294,950,950 1,159,277,845 4,356,762 14,631,128,276 27,104,389,931 Net Asset Value (NAV) Per Share (Note-37) 66.83 The Notes are an integral part of the Financial Statements. Approved and authorised for issue by the Board of Directors on October 28, 2019 and signed for and on behalf of the Board : Beximco Pharmaceuticals Limited Statement of Changes in Equity For the Year ended June 30, 2019 Salman F Rahman Vice Chairman Dhaka October 28, 2019 Per our report of even date M.J. Abedin & Co. Chartered Accountants Nazmul Hassan Managing Director Mohammad Ali Nawaz Chief Financial Officer
Image of page 31
Beximco Pharmaceuticals Limited Statement of Cash Flows For the Year ended June 30, 2019 Amount in Taka Notes July 2018 - June 2019 July 2017 - June 2018 Cash Flows from Operating Activities : Receipts from Customers and Others 20,798,619,790 16,851,875,991 Payments to Suppliers and Employees (16,112,060,651) (13,768,549,304) Cash Generated from Operations 4,686,559,139 3,083,326,687 Interest Paid (938,074,846) (512,099,369) Interest Received 36,457,527 54,928,425 Income Tax Paid (1,058,484,114) (778,088,709) Net Cash Generated from Operating Activities 39 2,726,457,706 1,848,067,034 Cash Flows from Investing Activities : Acquisition of Property, Plant and Equipment (4,337,220,303) (4,947,915,606) Intangible Assets (128,619,282) (106,921,036) Investment in Subsidiary (19,999,900) (2,125,186,000) Disposal of Property, Plant and Equipment 17,267,628 1,354,100 Dividend Received 1,491,901 1,504,092 Decrease in Short Term Investment 16,032,638 547,179,732 Net Cash Used in Investing Activities (4,451,047,318) (6,629,984,718) Cash Flows from Financing Activities : Net Increase /(Decrease) in Long Term Borrowings (1,296,871,228) 1,902,090,586 Net Increase/(Decrease) in Short Term Borrowings 3,738,926,253 3,476,665,586 Dividend Paid (504,483,537) (502,757,959) Net Cash Generated from Financing Activities 1,937,571,488 4,875,998,213 Increase/(Decrease) in Cash and Cash Equivalents 212,981,876 94,080,529 Cash and Cash Equivalents at Beginning of Year 369,108,554 275,028,025 Effect of exchange rate changes on Cash and Cash Equivalents 215,618 - Cash and Cash Equivalents at End of Year 14 582,306,048 369,108,554
Image of page 32
Image of page 33

You've reached the end of your free preview.

Want to read all 92 pages?

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture